Akero Therapeutics (AKRO) News Today $38.08 +0.48 (+1.28%) Closing price 04:00 PM EasternExtended Trading$37.84 -0.24 (-0.63%) As of 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Akero Therapeutics, Inc. (NASDAQ:AKRO) is University of Wisconsin Foundation's 6th Largest PositionUniversity of Wisconsin Foundation decreased its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,630 shares ofApril 15 at 8:18 AM | marketbeat.comOptimize Financial Inc Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Optimize Financial Inc purchased a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 8,336 shares of the companyApril 15 at 6:57 AM | marketbeat.comF M Investments LLC Invests $1.27 Million in Akero Therapeutics, Inc. (NASDAQ:AKRO)F M Investments LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 45,778 shares of the company's stock, valued at apprApril 14 at 5:41 AM | marketbeat.comJPMorgan Chase & Co. Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)JPMorgan Chase & Co. raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 528,207 shares of the company's stock after acqApril 14 at 3:29 AM | marketbeat.comSei Investments Co. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)Sei Investments Co. bought a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 10,887 shares of the company's stock, valued at approximately $30April 13 at 3:32 AM | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 30,000 SharesApril 12 at 5:37 AM | insidertrades.comExodusPoint Capital Management LP Grows Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)ExodusPoint Capital Management LP raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 15.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 55,207 shares of the company's stock after buyApril 12 at 4:52 AM | marketbeat.comVanguard Group Inc. Has $103.06 Million Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Vanguard Group Inc. grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 0.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,704,411 shares of the company's stock after acquiring an addiApril 12 at 3:37 AM | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 6,250 Shares of StockApril 11, 2025 | insidertrades.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives $76.29 Consensus PT from BrokeragesApril 10, 2025 | americanbankingnews.comSchroder Investment Management Group Reduces Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Schroder Investment Management Group decreased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 86.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,615 shares of the cApril 9, 2025 | marketbeat.com151,200 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Springhill Fund Asset Management HK Co LtdSpringhill Fund Asset Management HK Co Ltd purchased a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 151,200 shares of the company's sApril 8, 2025 | marketbeat.comKLP Kapitalforvaltning AS Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)KLP Kapitalforvaltning AS purchased a new stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,000 shares of the company's stock, valued at approximatelyApril 8, 2025 | marketbeat.comAmerican Century Companies Inc. Acquires 39,932 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)American Century Companies Inc. grew its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 55.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 112,442 shares of the compaApril 8, 2025 | marketbeat.comINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law FirmApril 7, 2025 | investing.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received an average recommendation of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1 year target price among analysts thatApril 7, 2025 | marketbeat.comAlliancebernstein L.P. Trims Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO)Alliancebernstein L.P. lessened its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,839,281 shares of the company's stock after selling 177,807 shares durApril 7, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Trading 7.3% Higher - Here's WhyAkero Therapeutics (NASDAQ:AKRO) Shares Up 7.3% - Here's WhyApril 4, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Position Trimmed by Wellington Management Group LLPWellington Management Group LLP trimmed its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,376,961 shares of the company's stoApril 4, 2025 | marketbeat.comAkero Therapeutics Enters Oversold Territory (AKRO)April 3, 2025 | nasdaq.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comNEOS Investment Management LLC Has $894,000 Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)NEOS Investment Management LLC lowered its holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 25.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 32,150 shares of theApril 1, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Insider Buying ActivityAkero Therapeutics (NASDAQ:AKRO) Shares Gap Up on Insider Buying ActivityMarch 29, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Director Acquires $2,177,500.00 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham purchased 50,000 shares of the company's stock in a transaction dated Thursday, March 27th. The shares were bought at an average cost of $43.55 per share, for a total transaction of $2,177,500.00. Following the acquisition, the director now owns 1,200,000 shares in the company, valued at approximately $52,260,000. The trade was a 4.35 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.March 28, 2025 | marketbeat.comG. Walmsley Graham Purchases 91,309 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) Director G. Walmsley Graham acquired 91,309 shares of Akero Therapeutics stock in a transaction dated Tuesday, March 25th. The shares were bought at an average cost of $44.75 per share, with a total value of $4,086,077.75. Following the transaction, the director now owns 1,091,309 shares in the company, valued at approximately $48,836,077.75. This trade represents a 9.13 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.March 28, 2025 | marketbeat.comG. Walmsley Graham Purchases 50,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMarch 28, 2025 | insidertrades.comAkero Therapeutics (NASDAQ:AKRO) Trading Down 6.3% - Here's WhyAkero Therapeutics (NASDAQ:AKRO) Trading Down 6.3% - Time to Sell?March 27, 2025 | marketbeat.comProficio Capital Partners LLC Invests $320,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)Proficio Capital Partners LLC bought a new stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,490 shares of the company's stock, valuedMarch 26, 2025 | marketbeat.comSimplify Asset Management Inc. Has $7.36 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO)Simplify Asset Management Inc. lowered its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 6.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 264,677 shares of the company's stock after selling 19,089 shares during the peMarch 24, 2025 | marketbeat.comIntech Investment Management LLC Buys 20,795 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)Intech Investment Management LLC raised its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 121.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 37,902 shares of the company'March 23, 2025 | marketbeat.comYiheng Capital Management L.P. Has $18.53 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Yiheng Capital Management L.P. reduced its stake in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 12.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 666,145 shares of the company's stock afteMarch 22, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Stock Position Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. lifted its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 540,692 shMarch 21, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $44.76, for a total transaction of $447,600.00. Following the sale, the insider now owns 95,034 shares of the company's stock, valued at $4,253,721.84. This trade represents a 9.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.March 19, 2025 | marketbeat.comKennondale Capital Management LLC Makes New $785,000 Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO)Kennondale Capital Management LLC bought a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 28,217 shares of thMarch 19, 2025 | marketbeat.comCatriona Yale Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMarch 19, 2025 | insidertrades.comBank of New York Mellon Corp Cuts Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO)Bank of New York Mellon Corp lessened its position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 200,430 shares of the company's stock after selling 6,414 sharesMarch 17, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by AlphaQuest LLCAlphaQuest LLC increased its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 32,588.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,172 shares of the company's stock after purchaMarch 16, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) COO Jonathan Young sold 607 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the transaction, the chief operating officer now owns 200,540 shares in the company, valued at approximately $9,000,235.20. This trade represents a 0.30 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.March 15, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 614 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 614 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total transaction of $27,556.32. Following the sale, the insider now owns 95,034 shares in the company, valued at $4,265,125.92. The trade was a 0.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CFO Sells $30,338.88 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CFO William Richard White sold 676 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $30,338.88. Following the completion of the transaction, the chief financial officer now owns 61,959 shares of the company's stock, valued at approximately $2,780,719.92. The trade was a 1.08 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng Sells 1,738 SharesAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 1,738 shares of the stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $78,001.44. Following the completion of the sale, the chief executive officer now owns 654,324 shares of the company's stock, valued at approximately $29,366,061.12. This trade represents a 0.26 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.March 15, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 607 SharesMarch 15, 2025 | insidertrades.comGreat Lakes Advisors LLC Purchases Shares of 193,384 Akero Therapeutics, Inc. (NASDAQ:AKRO)Great Lakes Advisors LLC acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 193,384 shares of the company's stock, valueMarch 14, 2025 | marketbeat.comInsider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Sells 30,000 Shares of StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 30,000 shares of Akero Therapeutics stock in a transaction on Monday, March 10th. The stock was sold at an average price of $41.77, for a total value of $1,253,100.00. Following the completion of the sale, the chief executive officer now directly owns 656,062 shares of the company's stock, valued at approximately $27,403,709.74. The trade was a 4.37 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.March 13, 2025 | marketbeat.comAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 5.5% - Here's What HappenedAkero Therapeutics (NASDAQ:AKRO) Stock Price Up 5.5% - Here's WhyMarch 13, 2025 | marketbeat.comAndrew Cheng Sells 30,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) StockMarch 13, 2025 | insidertrades.comProficio Capital Partners LLC Acquires Shares of 11,490 Akero Therapeutics, Inc. (NASDAQ:AKRO)Proficio Capital Partners LLC bought a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 11,490 shares of the company'sMarch 12, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Buy" from AnalystsAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) has received a consensus rating of "Buy" from the nine research firms that are presently covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a buy recommendation. The average 1 year price target among broMarch 11, 2025 | marketbeat.comAkero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $556,625.00 in StockAkero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Timothy Rolph sold 12,500 shares of Akero Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $44.53, for a total value of $556,625.00. Following the completion of the sale, the insider now directly owns 170,237 shares in the company, valued at $7,580,653.61. This represents a 6.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.March 8, 2025 | marketbeat.comEvercore ISI Reaffirms Their Buy Rating on Akero Therapeutics (AKRO)March 7, 2025 | markets.businessinsider.com Remove Ads Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRO Media Mentions By Week AKRO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKRO News Sentiment▼1.080.80▲Average Medical News Sentiment AKRO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKRO Articles This Week▼148▲AKRO Articles Average Week Remove Ads Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Qiagen News Viatris News Roivant Sciences News Lantheus News Revolution Medicines News BridgeBio Pharma News TG Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKRO) was last updated on 4/15/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AKRO Stock Free AKRO Stock Alerts